Forget Single Genes: CRISPR Now Cuts & Splices Whole Chromosomes

The technique will enable synthetic biologists to take on “grand challenges,” says, Anne S. Meyer, an associate professor of biology, such as “writing of information to DNA and storing it in a bacterial genome or creating new hybrid bacterial species that can carry out novel [metabolic reactions] for biochemistry or materials production.”

With a new CRISPR-based editor, biologists can now edit lengthy spans of DNA. ISTOCK.COM/MELETIOS VERRAS

By Robert F. Service | Aug 29, 2019 |  Science Magazine

Imagine a word processor that allowed you to change letters or words but balked when you tried to cut or rearrange whole paragraphs. Biologists have faced such constraints for decades. They could add or disable genes in a cell or even—with the genome-editing technology CRISPR—make precise changes within genes. Those capabilities have led to recombinant DNA technology, genetically modified organisms, and gene therapies. But a long-sought goal remained out of reach: manipulating much larger chunks of chromosomes in Escherichia coli, the workhorse bacterium. Now, researchers report they’ve adapted CRISPR and combined it with other tools to cut and splice large genome fragments with ease.

“This new paper is incredibly exciting and a huge step forward for synthetic biology,” says Anne Meyer, a synthetic biologist at the University of Rochester in New York who was not involved in the paper published in this week’s issue of Science. The technique will enable synthetic biologists to take on “grand challenges,” she says, such as “writing of information to DNA and storing it in a bacterial genome or creating new hybrid bacterial species that can carry out novel [metabolic reactions] for biochemistry or materials production.”

The tried and true tools of genetic engineering simply can’t handle long stretches of DNA. Restriction enzymes, the standard tool for cutting DNA, can snip chunks of genetic material and join the ends to form small circular segments that can be moved out of one cell and into another. (Stretches of linear DNA don’t survive long before other enzymes, called endonucleases, destroy them.) But the circles can accommodate at most a couple of hundred thousand bases, and synthetic biologists often want to move large segments of chromosomes containing multiple genes, which can be millions of bases long or more. “You can’t get very large pieces of DNA in and out of cells,” says Jason Chin, a synthetic biologist at the Medical Research Council (MRC) Laboratory of Molecular Biology in Cambridge, U.K.

What’s more, those cutting and pasting tools can’t be targeted precisely, and they leave unwanted DNA at the splicing sites—the equivalent of genetic scars. The errors build up as more changes are made. Another problem is that traditional editing tools can’t faithfully glue large segments together. These issues can be a deal-breaker when biologists want to make hundreds or thousands of changes to an organism’s genome, says Chang Liu, a synthetic biologist at the University of California, Irvine.

Now, Chin and his MRC colleagues report they have solved these problems. First, the team adapted CRISPR to precisely excise long stretches of DNA without leaving scars. They then altered another well-known tool, an enzyme called lambda red recombinase, so it could glue the ends of the original chromosome—minus the removed portion—back together, as well as fuse the ends of the removed portion. Both circular strands of DNA are protected from endonucleases. The technique can create different circular chromosome pairs in other cells, and researchers can then swap chromosomes at will, eventually inserting whatever chunk they choose into the original genome. “Now, I can make a series of changes in one segment and then another and combine them together. That’s a big deal,” Liu says.

The new tools will bolster industrial biotechnology by making it easier to vary the levels of proteins that microbes make, Liu and others say. They also promise an easy way to rewrite bacterial genomes wholesale, Meyer adds. One such project aims to alter genomes so they can code not just for proteins’ normal 20 amino acids, but also for large numbers of nonnatural amino acids throughout the genome. That could lead to synthetic life forms capable of producing molecules far beyond the reach of natural organisms.

TRNDS 2019

University of Rochester
Saunders Research Building
Helen Wood Hall Auditorium
255 Crittenden Blvd
Rochester, NY 14642

Date: Friday, September 13
Time: 7:30 am – 4:00pm

TRNDS News

Sign-up for TRNDS updates and rare disease news

  • New Grants will Accelerate Clinical Trials in Rare Neurological Disorders
    READ MORE
  • Neurogene Offers Access to Genetic Testing for Lysosomal Storage Disease
    READ MORE
  • NIH launches 5-year, $10 million study on acute flaccid myelitis
    READ MORE
  • Study refines ALS risk among first-degree relatives of patients with disease
    READ MORE
  • NCATS Director Warns of 'Poorly Understood Public Health Implications of Rare Diseases'
    READ MORE
  • Speeding Up Drug Discovery for Brain Diseases
    READ MORE
  • NIH-Funded Project Aims to Build a ‘Google’ for Biomedical Data
    READ MORE
  • Rare Disease Groups Seek Public Support to Renew Newborn Screening Act in Senate
    READ MORE
  • Jsyne Gershkowitz, Amicus Therapeutics, TRNDS 2019
    (Podcast) Get to know Jayne Gershkowitz, Chief Patient Advocate at Amicus Therapeutics
    READ MORE
  • PJ Brooks, NCATS, NIH, TRNDS
    Meet TRNDS 2019 Speaker PJ Brooks
    READ MORE
  • Rare Pediatric Disease PRVs: FDA Updates Guidance
    READ MORE
  • Batten Disease Study
    Neurogene Opens Natural History Study of CLN7, CLN5 Diseases at UT Southwestern
    READ MORE
  • C-Path and NORD Collaborate to Launch Rare Disease Data Platform
    READ MORE
  • TRNDS 2019 speaker Tauna Batiste, BDSRA
    Meet TRNDS Speaker Tauna Batiste
    READ MORE
  • HD Patients Prefer Less Invasive, No-Placebo Gene Therapy Trials
    READ MORE
  • Evidation & Eli Lilly Study Uses Apple Devices, Apps to Predict Cognitive Impairment
    READ MORE
  • 'Dr. Google' Helps Some Patients Diagnose a Rare Disease
    READ MORE
  • Antisense Drugs for HD, ALS & Prion Could Meet the Need for Brain Treatments
    READ MORE
  • Ultragenyx Partners with GeneTx to Advance Treatment for Angelman Syndrome
    READ MORE
  • Netflix's Medical Investigation Docuseries 'Diagnosis'
    READ MORE
  • NIH All of Us Project Tops 270,000 Sign-ups
    READ MORE
  • FDA Cancer Office Taps Syapse for Real-world Evidence Development
    READ MORE
  • Gene Linked to Rare Neurological Disorder May Play a Role in Alzheimer’s
    READ MORE
  • Gene Therapy Developers Issue Principles for Human Genome Editing
    Gene Therapy Developers Issue Principles for Human Genome Editing
    READ MORE
  • Forget Single Genes: CRISPR Now Cuts & Splices Whole Chromosomes
    READ MORE
  • Benjjamin Schlatka MC10 TRNDS
    TRNDS Speaker Benjamin Schlatka, MC10
    READ MORE
  • TRNDS Danielle Edwards Jett Foundation
    TRNDS Speaker Danielle Edwards, Jett Foundation
    READ MORE
  • His daughter has a rare disorder. He’s developing a novel gene therapy.
    READ MORE
  • A Doctor Tested a New Treatment on Himself, Now it's Saving Other Lives
    READ MORE
  • Study Presents Clinical, Genetic Landscape of Pompe Disease
    READ MORE

Latest Tweets

TRNDS Speakers

Room Block

Hilton Garden Inn
Rochester/University
Medical Center

30 Celebration Drive
Rochester, NY 14620

Phone: 585-424-4404

TRNDS Rate: $149/night